Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agenus Gets FDA Priority Review of Balstilimab in Cervical Cancer

06/17/2021 | 07:16am EDT

By Colin Kellaher

Agenus Inc. on Thursday said the U.S. Food and Drug Administration granted priority review to its biologics license application for balstilimab for the treatment of recurrent or metastatic cervical cancer.

The Lexington, Mass., clinical-stage immuno-oncology company said the agency set a target action date of Dec. 16 for the application, which covers balstilimab in cervical cancer with disease progression on or after chemotherapy.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

Agenus said cervical cancer claims the lives of more than 300,000 women around the world each year, adding that current therapies for recurrent or metastatic cervical cancer are limited to a small subset of patients with limited benefit.

Shares of Agenus, which closed Wednesday at $5, rose nearly 6% in premarket trading Thursday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

06-17-21 0916ET

All news about AGENUS INC.
07/09Agenus Inc. acquired Biomanufacturing Center in Vacaville California, US Stat..
CI
07/07Agenus to Participate in Resistance-Focused Oncology Panel at the William Bla..
GL
07/06AGENUS : Says FDA Accepts Investigational New Drug Application for Cancer Drug C..
MT
07/06Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of..
GL
07/06Agenus Inc. Announces the Closing of its Global Exclusive License with Bristo..
CI
07/06Agenus Inc. Announces the U.S. Food and Drug Administration Clearance of an I..
CI
06/29AGENUS : B. Riley Raises Agenus' PT to $11 from $8, Notes Value Accretive Cataly..
MT
06/21AGENUS : to Participate in the Raymond James 2021 Human Health Innovation Confer..
AQ
06/17Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candid..
RE
06/17AGENUS' : Biologics License Application for Balstilimab Accepted by FDA for Prio..
MT
More news
Financials (USD)
Sales 2021 60,0 M - -
Net income 2021 -228 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,46x
Yield 2021 -
Capitalization 1 250 M 1 250 M -
Capi. / Sales 2021 20,8x
Capi. / Sales 2022 12,6x
Nbr of Employees 359
Free-Float 86,6%
Chart AGENUS INC.
Duration : Period :
Agenus Inc. Technical Analysis Chart | AGEN | US00847G7051 | MarketScreener
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,62 $
Average target price 9,00 $
Spread / Average Target 60,1%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Jennifer S Buell President & Chief Operating Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven O’Day Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.76.73%1 195
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-25.21%32 170
SEAGEN INC.-16.87%28 525